Candel Therapeutics, Inc. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing its financial condition, operational status, and risk factors as of that date.

Key Highlights

  • Shares outstanding: As of August 6, 2026, the company had 76,518,565 shares of common stock, $0.01 par value per share, outstanding.
  • No product revenue: The company disclosed it has not generated any revenue from product sales and expects to continue incurring significant expenses and increasing operating losses for the foreseeable future.
  • Additional funding required: According to the filing, the company will need to raise substantial additional funding and, if unable to do so, may be forced to delay, reduce, or eliminate product development programs or initiate steps to cease operations.
  • Key pipeline candidates: The company's business is described as dependent on aglatimagene besadenovec (previously CAN-2409) and linoserpaturev (previously CAN-3110), both of which require additional development before regulatory approval can be sought.
  • Company classifications: The registrant is identified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
  • Existing indebtedness: The filing notes the company has incurred indebtedness under the RTW Purchase Agreement, which currently imposes restrictions on the company's operating and financial flexibility.

Candel Therapeutics Outlines Pipeline Status and Financial Risks in Q2 2026 Quarterly Report

Candel Therapeutics, Inc. (NASDAQ:CADL), a biopharmaceutical company headquartered at 117 Kendrick St, Suite 450, Needham, MA 02494, submitted its Form 10-Q for the quarterly period ended June 30, 2026. The filing was made under Commission File Number 001-40629 and covers Candel's operational and financial condition as a clinical-stage company with no product sales revenue to date.

According to the filing, the company's principal product candidates are aglatimagene besadenovec and linoserpaturev, both of which require additional development before the company may seek regulatory approval. The filing notes that the company holds a license agreement with Mass General Brigham (MGB) and describes its business as subject to the terms of the RTW Purchase Agreement, which the filing states imposes restrictions on Candel's operating and financial flexibility. The company disclosed it "has not generated any revenue from product sales" and characterized the need to raise additional capital as a principal risk, stating that failure to do so could force the company to "delay, reduce or eliminate some of our product development programs or commercialization efforts or initiate steps to cease operations."

The filing identifies the company as an emerging growth company and smaller reporting company. Forward-looking statements contained in the Form 10-Q, as noted by the company, are based on management's beliefs and assumptions and are subject to known and unknown risks and uncertainties, with the company directing readers to the Risk Factors section in Part II, Item 1A of the filing for a fuller description of those risks.

What Was Disclosed

Candel Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, disclosing that it has generated no product revenue, requires additional funding, holds two principal pipeline candidates in development, and carries existing indebtedness under the RTW Purchase Agreement.